Robertson Lab

Dr. Gregory Robertson’s research is focused on the field of Mycobacterium tuberculosis host-pathogen interactions with emphasis on the development of novel preclinical tools, use of TB mouse models for drug evaluation, and evaluation of drug activity and resistance in vitro and in vivo. He also leads preclinical animal studies as part of the Consortium for Applied Microbial Metrics including other investigators from the University of California San Francisco, Denver VA Medical Center, and CU Anschutz Medical Campus.

We are looking for talented researchers to join our team!

Contact to Join Our Team

research project

TB Drug Accelerator

Goal: (i) To identify in vivo active compounds, (ii) to enable more effective hit-to-lead and lead optimization cycles, and (iii) to support the selection of pre-clinical candidates as a service for the TB Drug Accelerator researchers.

view project
research project

Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis

Goal: This proposal seeks to continue the development of the spectinamides as combination agents for MDR-TB, with a focus on their utility to treat chronic infections and as tools to understand the role of native efflux in tuberculosis drug persistence.

research project


Goal: Tuberculosis is difficult to treat because many drugs are hindered in their ability to penetrate tissues that harbor the pathogen. We propose to overcome this problem by developing new technology based on peptides that recognize and home to TB-infected tissue as a means to target drug payloads to where they are needed most.

research project

Lead Optimization of Novel Azetidine Compound Series Demonstrating New Mechanism of Action for the Treatment of Tuberculosis

Goal: Development of novel tryptophan synthesis inhibitors with activity against M. tuberculosis in vivo.

research project

Validation of Mtb ribosomal RNA as a PD marker of treatment response

Goal: The primary output from this investment is the rapid and comprehensive characterization of novel RNA-based PD markers as measures of treatment-shortening potency.


Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.

Robertson GT, Ramey ME, Massoudi LM, Carter CL, Zimmerman M, Kaya F, Graham BG, Gruppo V, Hastings C, Woolhiser LK, Scott DWL, Asay BC, Eshun-Wilson F, Maidj E, Podell BK, Vásquez JJ, Lyons MA, Dartois V, Lenaerts AJ.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0058321. doi: 10.1128/AAC.00583-21. Epub 2021 Aug 9.
PMID: 34370580

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.

Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang L, Davis JL, Nguyen NV, Nguyen HV, Nguyen ATV, Phan H, Wilusz C, Podell BK, Sanoussi ND, de Jong BC, Merle CS, Affolabi D, McIlleron H, Garcia-Cremades M, Maidji E, Eshun-Wilson F, Aguilar-Rodriguez B, Karthikeyan D, Mdluli K, Bansbach C, Lenaerts AJ, Savic RM, Nahid P, Vásquez JJ, Voskuil MI.
Nat Commun. 2021 May 18;12(1):2899. doi: 10.1038/s41467-021-22833-6.PMID: 34006838

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.

Robertson GT, Ektnitphong VA, Scherman MS, McNeil MB, Dennison D, Korkegian A, Smith AJ, Halladay J, Carter DS, Xia Y, Zhou Y, Choi W, Berry PW, Mao W, Hernandez V, Alley MRK, Parish T, Lenaerts AJ.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02071-18. doi: 10.1128/AAC.02071-18. Print 2019 Apr.

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O’Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M.
Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun. 

Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. 

Robertson GT, Scherman MS, Bruhn DF, Liu J, Hastings C, McNeil MR, Butler MM, Bowlin TL, Lee RB, Lee RE, Lenaerts AJ.
Antimicrob Chemother. 2017 Mar 1;72(3):770-777. doi: 10.1093/jac/dkw467. 

more publications


Gregory Robertson, Ph.D.

Lab Principal Investigator [PI]
Assistant Professor

Lisa Woolhiser, M.S.

Research Associate IV

Lisa Massoudi

Research Associate III

Michelle Ramey, M.S.

Research Associate III

Allison Bauman

Research Associate II

Courtney Hastings

Research Associate II

Isabelle Jones

Research Associate I

Ashley Gerwing

Student Researcher

Johannah Gillespie

Student Researcher

Noah Hoglund

Student Researcher

Amanda Houghton

Student Researcher

Isabele Johnson

Student Researcher

Tess Kilberg

Student Researcher

Camryn Nesiba

Student Researcher

Gabriell Papp

Student Researcher

Braden Pate

Student Researcher

Jacy Stampes

Student Researcher

Sierra Johnson

Student Researcher

Erin Brady

Student Researcher

news and updates view all